Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04278222 | Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) | unknown | Phase 2 | 24 | Shanghai Changzheng HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06387810 | Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer(undetermined) | unknown | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Jul 10, 2024 |
| clinicaltrials |
| NCT04715633 | PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05739045 | Nivolumab Combined With SOX Used in the Perioperative Treatment | unknown | Phase 2 | 46 | Xiangdong ChengOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02355379 | Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over(ADAGE) | unknown | Phase 3 | 774 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03760822 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients(SOCRATE) | unknown | Phase 2 | 112 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03959293 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | unknown | Phase 2 | 107 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04891900 | TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma | unknown | N/A | 25 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06489288 | ERAS in Totally Laparoscopic Total Gastrectomy for Gastric Cancer | unknown | N/A | 2,656 | Xijing HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05229003 | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06090656 | Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)(BEST) | unknown | Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485713 | Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC | unknown | Phase 2 | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05606848 | To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer | unknown | N/A | 350 | Fresenius Kabi Sino-Swed Pharmaceutical Corp. LtdINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06456281 | Multi-omics Model for Pancreatic Cancer Screening Using cfDNA | unknown | — | 480 | Fudan UniversityOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06482008 | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 0 | Jul 1, 2024 | clinicaltrials |
| NCT04896684 | Chronic Intestinal Pathologies Analytical Cohort at TouLouse(CAPITOL) | unknown | — | 300 | University Hospital, ToulouseOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
| NCT06326892 | Natural Orifice Specimen Extraction in Low Rectal Cancer Surgery(NOSES) | unknown | — | 350 | Istituto Clinico HumanitasOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475196 | Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC | unknown | — | 90 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475287 | HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475417 | Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer | unknown | Phase 2 | 42 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06472063 | Upfront Surgery Versus NeoAdjuvant Chemotherapy Followed by Surgery for Resectable Advanced Gastric Cancer: SNAC Study(SNAC) | unknown | — | 684 | San Luigi Gonzaga HospitalOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT05444088 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 129 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05880992 | Trimodal Prehabilitation in Colorectal Cancer Patients(PrehabCRC) | unknown | N/A | 50 | Jordan LeitchOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05240625 | Clinical Efficacy Evaluation of a Computer-aided Colonoscopy as Compared With the Standard Colonoscopy. | unknown | N/A | 1,500 | National Taiwan University HospitalOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06464614 | Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. | unknown | Phase 2 | 54 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT03867799 | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | unknown | Phase 2 | 25 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05766748 | Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06458725 | Assessment of DW-MRI Measures : Reproducibility and Repeatability in Pelvic Imaging on MR-Linac With Healthy Volunteers(PILLAR) | unknown | N/A | 30 | Jules Bordet InstituteOTHER | 0 | Jun 14, 2024 | clinicaltrials |
| NCT05717738 | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma(CCGLC-008) | unknown | — | 300 | Tongji HospitalOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06456229 | Time to Return of Bowel Function Following Perioperative Probiotics in Colorectal Cancer Surgery(PICCS-1) | unknown | N/A | 162 | National University Hospital, SingaporeOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06018896 | Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer(PTCA199-4) | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06443307 | Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan | unknown | — | 933 | Peking UniversityOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT05304234 | Liver Cancer Disparities in American Indian and Alaska Native Persons | unknown | Phase 2 | 200 | University of WashingtonOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06434753 | Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease. | unknown | Phase 3 | 300 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03356236 | Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation | unknown | — | 828 | Yue HanOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06436976 | The Effect of Probiotics ATG-F4 in Cancer Patients | unknown | Phase 2 | 30 | Chungnam National University HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06437678 | Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06434090 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06432205 | The Effect of MDT Plus SDM on Survival Benefit of Advanced Gastric Cancer | unknown | — | 121 | Peking UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05605197 | U87 CART in Treatment of Advanced Solid Tumor | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06429865 | Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma | unknown | N/A | 1,000 | Changhai HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT04799548 | A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma | unknown | Phase 2 | 71 | Shanghai Zhongshan HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06423144 | PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7 | unknown | — | 150 | Shanghai Zhongshan HospitalOTHER | 0 | May 21, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 10, 2024source: clinicaltrials